A 24 week, multicenter, open evaluation of the clinical effectiveness of the once-daily 10 cm2 Exelon® patch formulation in patients with probable Alzheimer’s disease (MMSE10-26)

Update Il y a 4 ans
Reference: EUCTR2007-001383-70

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To support the clinical effectiveness of Exelon® target patch size 10 cm² by determining in a real life setting the percentage of patients who stay on the Exelon® target patch size of 10 cm² for at least 8 weeks. This proportion will then be compared to historic data with the percentage of patients who could reach Exelon® capsule target dose of 12 mg and stay on it at least 8 weeks, in previous Exelon trials.


Inclusion criteria

  • probable Alzheimer's disease

Links